MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

BACKGROUND: Although the mitogen-activated protein kinases (MAPK) pathway is hyperactive in head and neck cancer (HNC), inhibition of MEK1/2 in HNC patients has not shown clinically meaningful activity. Therefore, we aimed to characterize the effect of MEK1/2 inhibition on the tumor microenvironment...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasad, Manu, Zorea, Jonathan, Jagadeeshan, Sankar, Shnerb, Avital B, Mathukkada, Sooraj, Bouaoud, Jebrane, Michon, Lucas, Novoplansky, Ofra, Badarni, Mai, Cohen, Limor, Yegodayev, Ksenia M, Tzadok, Sapir, Rotblat, Barak, Brezina, Libor, Mock, Andreas, Karabajakian, Andy, Fayette, Jérôme, Cohen, Idan, Cooks, Tomer, Allon, Irit, Dimitstein, Orr, Joshua, Benzion, Kong, Dexin, Voronov, Elena, Scaltriti, Maurizio, Carmi, Yaron, Conde-Lopez, Cristina, Hess, Jochen, Kurth, Ina, Morris, Luc G T, Saintigny, Pierre, Elkabets, Moshe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928405/
https://www.ncbi.nlm.nih.gov/pubmed/35292516
http://dx.doi.org/10.1136/jitc-2021-003917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928405/
https://www.ncbi.nlm.nih.gov/pubmed/35292516
http://dx.doi.org/10.1136/jitc-2021-003917

Ejemplares similares